Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Targeting mutant p53 in cancer: the latest insights.

Di Agostino S, Fontemaggi G, Strano S, Blandino G, D'Orazi G.

J Exp Clin Cancer Res. 2019 Jul 5;38(1):290. doi: 10.1186/s13046-019-1302-0.

2.

Wild type- and mutant p53 proteins in mitochondrial dysfunction: emerging insights in cancer disease.

Blandino G, Valenti F, Sacconi A, Di Agostino S.

Semin Cell Dev Biol. 2019 May 23. pii: S1084-9521(18)30163-0. doi: 10.1016/j.semcdb.2019.05.011. [Epub ahead of print] Review.

PMID:
31112799
3.

Long Non-coding MIR205HG Depletes Hsa-miR-590-3p Leading to Unrestrained Proliferation in Head and Neck Squamous Cell Carcinoma.

Di Agostino S, Valenti F, Sacconi A, Fontemaggi G, Pallocca M, Pulito C, Ganci F, Muti P, Strano S, Blandino G.

Theranostics. 2018 Feb 12;8(7):1850-1868. doi: 10.7150/thno.22167. eCollection 2018.

4.

New therapeutic strategies to treat human cancers expressing mutant p53 proteins.

Blandino G, Di Agostino S.

J Exp Clin Cancer Res. 2018 Feb 15;37(1):30. doi: 10.1186/s13046-018-0705-7. Review.

5.

The mutant p53-ID4 complex controls VEGFA isoforms by recruiting lncRNA MALAT1.

Pruszko M, Milano E, Forcato M, Donzelli S, Ganci F, Di Agostino S, De Panfilis S, Fazi F, Bates DO, Bicciato S, Zylicz M, Zylicz A, Blandino G, Fontemaggi G.

EMBO Rep. 2017 Aug;18(8):1331-1351. doi: 10.15252/embr.201643370. Epub 2017 Jun 26.

6.

Sox2 is not required for melanomagenesis, melanoma growth and melanoma metastasis in vivo.

Cesarini V, Guida E, Todaro F, Di Agostino S, Tassinari V, Nicolis S, Favaro R, Caporali S, Lacal PM, Botti E, Costanzo A, Rossi P, Jannini EA, Dolci S.

Oncogene. 2017 Aug;36(31):4508-4515. doi: 10.1038/onc.2017.53. Epub 2017 Apr 3.

PMID:
28368402
7.

Type 5 phosphodiesterase regulates glioblastoma multiforme aggressiveness and clinical outcome.

Cesarini V, Martini M, Vitiani LR, Gravina GL, Di Agostino S, Graziani G, D'Alessandris QG, Pallini R, Larocca LM, Rossi P, Jannini EA, Dolci S.

Oncotarget. 2017 Feb 21;8(8):13223-13239. doi: 10.18632/oncotarget.14656.

8.

MCM7 and its hosted miR-25, 93 and 106b cluster elicit YAP/TAZ oncogenic activity in lung cancer.

Lo Sardo F, Forcato M, Sacconi A, Capaci V, Zanconato F, Di Agostino S, Del Sal G, Pandolfi PP, Strano S, Bicciato S, Blandino G.

Carcinogenesis. 2017 Jan;38(1):64-75. doi: 10.1093/carcin/bgw110. Epub 2016 Oct 17.

9.

Mutant p53 proteins counteract autophagic mechanism sensitizing cancer cells to mTOR inhibition.

Cordani M, Oppici E, Dando I, Butturini E, Dalla Pozza E, Nadal-Serrano M, Oliver J, Roca P, Mariotto S, Cellini B, Blandino G, Palmieri M, Di Agostino S, Donadelli M.

Mol Oncol. 2016 Aug;10(7):1008-29. doi: 10.1016/j.molonc.2016.04.001. Epub 2016 Apr 12.

10.

Oncogenic Intra-p53 Family Member Interactions in Human Cancers.

Ferraiuolo M, Di Agostino S, Blandino G, Strano S.

Front Oncol. 2016 Mar 31;6:77. doi: 10.3389/fonc.2016.00077. eCollection 2016. Review.

11.

YAP enhances the pro-proliferative transcriptional activity of mutant p53 proteins.

Di Agostino S, Sorrentino G, Ingallina E, Valenti F, Ferraiuolo M, Bicciato S, Piazza S, Strano S, Del Sal G, Blandino G.

EMBO Rep. 2016 Feb;17(2):188-201. doi: 10.15252/embr.201540488. Epub 2015 Dec 21.

12.

Cynara scolymus affects malignant pleural mesothelioma by promoting apoptosis and restraining invasion.

Pulito C, Mori F, Sacconi A, Casadei L, Ferraiuolo M, Valerio MC, Santoro R, Goeman F, Maidecchi A, Mattoli L, Manetti C, Di Agostino S, Muti P, Blandino G, Strano S.

Oncotarget. 2015 Jul 20;6(20):18134-50.

13.

Cocoa, blood pressure, and cardiovascular health.

Ferri C, Desideri G, Ferri L, Proietti I, Di Agostino S, Martella L, Mai F, Di Giosia P, Grassi D.

J Agric Food Chem. 2015 Nov 18;63(45):9901-9. doi: 10.1021/acs.jafc.5b01064. Epub 2015 Jul 13. Review.

PMID:
26125676
14.

Gain of function mutant p53 proteins cooperate with E2F4 to transcriptionally downregulate RAD17 and BRCA1 gene expression.

Valenti F, Ganci F, Fontemaggi G, Sacconi A, Strano S, Blandino G, Di Agostino S.

Oncotarget. 2015 Mar 20;6(8):5547-66.

15.

Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine.

Fiorini C, Cordani M, Padroni C, Blandino G, Di Agostino S, Donadelli M.

Biochim Biophys Acta. 2015 Jan;1853(1):89-100. doi: 10.1016/j.bbamcr.2014.10.003. Epub 2014 Oct 13.

16.

Interaction of mutant p53 with p73: a Surface Plasmon Resonance and Atomic Force Spectroscopy study.

Santini S, Di Agostino S, Coppari E, Bizzarri AR, Blandino G, Cannistraro S.

Biochim Biophys Acta. 2014 Jun;1840(6):1958-64. doi: 10.1016/j.bbagen.2014.02.014. Epub 2014 Feb 24.

PMID:
24576672
17.

ATM kinase enables the functional axis of YAP, PML and p53 to ameliorate loss of Werner protein-mediated oncogenic senescence.

Fausti F, Di Agostino S, Cioce M, Bielli P, Sette C, Pandolfi PP, Oren M, Sudol M, Strano S, Blandino G.

Cell Death Differ. 2013 Nov;20(11):1498-509. doi: 10.1038/cdd.2013.101. Epub 2013 Aug 9.

18.

Gender, mutant p53 and PML: a growing "affaire" in tumor suppression and oncogenesis.

Di Agostino S, Strano S, Blandino G.

Cell Cycle. 2013 Jun 15;12(12):1824-5. doi: 10.4161/cc.25174. Epub 2013 Jun 5. No abstract available.

19.

Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells.

Masciarelli S, Fontemaggi G, Di Agostino S, Donzelli S, Carcarino E, Strano S, Blandino G.

Oncogene. 2014 Mar 20;33(12):1601-8. doi: 10.1038/onc.2013.106. Epub 2013 Apr 15.

PMID:
23584479
20.

PML Surfs into HIPPO Tumor Suppressor Pathway.

Strano S, Fausti F, Di Agostino S, Sudol M, Blandino G.

Front Oncol. 2013 Mar 1;3:36. doi: 10.3389/fonc.2013.00036. eCollection 2013.

21.

miR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer.

Sacconi A, Biagioni F, Canu V, Mori F, Di Benedetto A, Lorenzon L, Ercolani C, Di Agostino S, Cambria AM, Germoni S, Grasso G, Blandino R, Panebianco V, Ziparo V, Federici O, Muti P, Strano S, Carboni F, Mottolese M, Diodoro M, Pescarmona E, Garofalo A, Blandino G.

Cell Death Dis. 2012 Nov 15;3:e423. doi: 10.1038/cddis.2012.160.

22.

Hippo and rassf1a Pathways: A Growing Affair.

Fausti F, Di Agostino S, Sacconi A, Strano S, Blandino G.

Mol Biol Int. 2012;2012:307628. doi: 10.1155/2012/307628. Epub 2012 Jul 5.

23.

MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function.

Donzelli S, Fontemaggi G, Fazi F, Di Agostino S, Padula F, Biagioni F, Muti P, Strano S, Blandino G.

Cell Death Differ. 2012 Jun;19(6):1038-48. doi: 10.1038/cdd.2011.190. Epub 2011 Dec 23.

24.

Interaction of an anticancer peptide fragment of azurin with p53 and its isolated domains studied by atomic force spectroscopy.

Bizzarri AR, Santini S, Coppari E, Bucciantini M, Di Agostino S, Yamada T, Beattie CW, Cannistraro S.

Int J Nanomedicine. 2011;6:3011-9. doi: 10.2147/IJN.S26155. Epub 2011 Nov 24.

25.

Mutant p53 oncogenic functions are sustained by Plk2 kinase through an autoregulatory feedback loop.

Valenti F, Fausti F, Biagioni F, Shay T, Fontemaggi G, Domany E, Yaffe MB, Strano S, Blandino G, Di Agostino S.

Cell Cycle. 2011 Dec 15;10(24):4330-40. doi: 10.4161/cc.10.24.18682. Epub 2011 Dec 15.

PMID:
22134238
26.

The cancer-associated K351N mutation affects the ubiquitination and the translocation to mitochondria of p53 protein.

Muscolini M, Montagni E, Palermo V, Di Agostino S, Gu W, Abdelmoula-Souissi S, Mazzoni C, Blandino G, Tuosto L.

J Biol Chem. 2011 Nov 18;286(46):39693-702. doi: 10.1074/jbc.M111.279539. Epub 2011 Sep 27.

27.

Che-1 promotes tumor cell survival by sustaining mutant p53 transcription and inhibiting DNA damage response activation.

Bruno T, Desantis A, Bossi G, Di Agostino S, Sorino C, De Nicola F, Iezzi S, Franchitto A, Benassi B, Galanti S, La Rosa F, Floridi A, Bellacosa A, Passananti C, Blandino G, Fanciulli M.

Cancer Cell. 2010 Aug 9;18(2):122-34. doi: 10.1016/j.ccr.2010.05.027.

28.

Characterization of a new cancer-associated mutant of p53 with a missense mutation (K351N) in the tetramerization domain.

Muscolini M, Montagni E, Caristi S, Nomura T, Kamada R, Di Agostino S, Corazzari M, Piacentini M, Blandino G, Costanzo A, Sakaguchi K, Tuosto L.

Cell Cycle. 2009 Oct 15;8(20):3396-405. Epub 2009 Oct 24.

PMID:
19806023
29.

A combined atomic force microscopy imaging and docking study to investigate the complex between p53 DNA binding domain and Azurin.

Bizzarri AR, Di Agostino S, Andolfi L, Cannistraro S.

J Mol Recognit. 2009 Nov-Dec;22(6):506-15. doi: 10.1002/jmr.975.

PMID:
19642109
30.

Promyelocytic leukemia protein is required for gain of function by mutant p53.

Haupt S, di Agostino S, Mizrahi I, Alsheich-Bartok O, Voorhoeve M, Damalas A, Blandino G, Haupt Y.

Cancer Res. 2009 Jun 1;69(11):4818-26. doi: 10.1158/0008-5472.CAN-08-4010.

31.

PML, YAP, and p73 are components of a proapoptotic autoregulatory feedback loop.

Lapi E, Di Agostino S, Donzelli S, Gal H, Domany E, Rechavi G, Pandolfi PP, Givol D, Strano S, Lu X, Blandino G.

Mol Cell. 2008 Dec 26;32(6):803-14. doi: 10.1016/j.molcel.2008.11.019.

32.

The disruption of the protein complex mutantp53/p73 increases selectively the response of tumor cells to anticancer drugs.

Di Agostino S, Cortese G, Monti O, Dell'Orso S, Sacchi A, Eisenstein M, Citro G, Strano S, Blandino G.

Cell Cycle. 2008 Nov 1;7(21):3440-7. Epub 2008 Nov 16.

PMID:
18948736
33.

Mutant p53: an oncogenic transcription factor.

Strano S, Dell'Orso S, Di Agostino S, Fontemaggi G, Sacchi A, Blandino G.

Oncogene. 2007 Apr 2;26(15):2212-9. Review.

PMID:
17401430
34.

Mutant p53 proteins: between loss and gain of function.

Strano S, Dell'Orso S, Mongiovi AM, Monti O, Lapi E, Di Agostino S, Fontemaggi G, Blandino G.

Head Neck. 2007 May;29(5):488-96. Review.

PMID:
17123310
35.

Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation.

Di Agostino S, Strano S, Emiliozzi V, Zerbini V, Mottolese M, Sacchi A, Blandino G, Piaggio G.

Cancer Cell. 2006 Sep;10(3):191-202.

36.

17-beta-estradiol elicits genomic and non-genomic responses in mouse male germ cells.

Vicini E, Loiarro M, Di Agostino S, Corallini S, Capolunghi F, Carsetti R, Chieffi P, Geremia R, Stefanini M, Sette C.

J Cell Physiol. 2006 Jan;206(1):238-45.

PMID:
15991248
37.

Direct p53 transcriptional repression: in vivo analysis of CCAAT-containing G2/M promoters.

Imbriano C, Gurtner A, Cocchiarella F, Di Agostino S, Basile V, Gostissa M, Dobbelstein M, Del Sal G, Piaggio G, Mantovani R.

Mol Cell Biol. 2005 May;25(9):3737-51.

38.

Meiotic progression of isolated mouse spermatocytes under simulated microgravity.

Di Agostino S, Botti F, Di Carlo A, Sette C, Geremia R.

Reproduction. 2004 Jul;128(1):25-32.

PMID:
15232061
39.

Analysis of the gene expression profile of mouse male meiotic germ cells.

Rossi P, Dolci S, Sette C, Capolunghi F, Pellegrini M, Loiarro M, Di Agostino S, Paronetto MP, Grimaldi P, Merico D, Martegani E, Geremia R.

Gene Expr Patterns. 2004 May;4(3):267-81.

PMID:
15053975
40.

Phosphorylation of high-mobility group protein A2 by Nek2 kinase during the first meiotic division in mouse spermatocytes.

Di Agostino S, Fedele M, Chieffi P, Fusco A, Rossi P, Geremia R, Sette C.

Mol Biol Cell. 2004 Mar;15(3):1224-32. Epub 2003 Dec 10.

41.

Prolin-rich tyrosine kinase 2 (PYK2) expression and localization in mouse testis.

Chieffi P, Barchi M, Di Agostino S, Rossi P, Tramontano D, Geremia R.

Mol Reprod Dev. 2003 Jul;65(3):330-5.

PMID:
12784255
42.

The mechanism of docosahexaenoic acid-induced phospholipase D activation in human lymphocytes involves exclusion of the enzyme from lipid rafts.

Diaz O, Berquand A, Dubois M, Di Agostino S, Sette C, Bourgoin S, Lagarde M, Nemoz G, Prigent AF.

J Biol Chem. 2002 Oct 18;277(42):39368-78. Epub 2002 Jul 24.

43.

HMGA1 and HMGA2 protein expression in mouse spermatogenesis.

Chieffi P, Battista S, Barchi M, Di Agostino S, Pierantoni GM, Fedele M, Chiariotti L, Tramontano D, Fusco A.

Oncogene. 2002 May 16;21(22):3644-50.

44.

The MAPK pathway triggers activation of Nek2 during chromosome condensation in mouse spermatocytes.

Di Agostino S, Rossi P, Geremia R, Sette C.

Development. 2002 Apr;129(7):1715-27.

45.

Signaling through extracellular signal-regulated kinase is required for spermatogonial proliferative response to stem cell factor.

Dolci S, Pellegrini M, Di Agostino S, Geremia R, Rossi P.

J Biol Chem. 2001 Oct 26;276(43):40225-33. Epub 2001 Aug 13.

46.

Maize polyamine oxidase: primary structure from protein and cDNA sequencing.

Tavladoraki P, SchininĂ  ME, Cecconi F, Di Agostino S, Manera F, Rea G, Mariottini P, Federico R, Angelini R.

FEBS Lett. 1998 Apr 10;426(1):62-6.

Supplemental Content

Loading ...
Support Center